| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1161/01.CIR.0000078025.19258.28 |
| P698 | PubMed publication ID | 12821586 |
| P50 | author | Patrick W Serruys | Q63253317 |
| P2093 | author name string | J Eduardo Sousa | |
| Pedro A Lemos | |||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3003-3007 | |
| P577 | publication date | 2003-06-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Drug-eluting stents: cost versus clinical benefit | |
| P478 | volume | 107 |
| Q88865320 | 3D Printed Antibiotic and Chemotherapeutic Eluting Catheters for Potential Use in Interventional Radiology: In Vitro Proof of Concept Study |
| Q42187564 | A meta-analysis of clinical trials of paclitaxel- and sirolimus-eluting stents in patients with obstructive coronary artery disease |
| Q58589497 | A rapamycin derivative, biolimus, preferentially activates autophagy in vascular smooth muscle cells |
| Q37221177 | Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model |
| Q36728852 | BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease |
| Q28392226 | C(6)-Ceramide-Coated Catheters Promote Re-Endothelialization of Stretch-Injured Arteries |
| Q37388164 | Clinical outcomes with Biolimus (A9)™ eluting stent, 'BioMatrix' in diabetic patients--interim results from multicenter post market surveillance registry in India |
| Q39983846 | Controlled initial surge despite high drug fraction and high solubility |
| Q44369970 | Cost-effectiveness analysis of infrapopliteal drug-eluting stents. |
| Q36361226 | Cutaneous lymphomas--radiotherapeutic strategies |
| Q53387747 | Development of a probucol-releasing antithrombogenic drug eluting stent. |
| Q40726912 | Diffuse Interface Methods for Modeling Drug-Eluting Stent Coatings |
| Q24202607 | Endothelial progenitor cell capture stents versus drug-eluting stents for angina or acute coronary syndrome |
| Q38791109 | Enhanced biocompatibility of CD47-functionalized vascular stents |
| Q51094783 | Feasibility and safety of intra-coronary Beta irradiation with 144Ce/Pr for prevention of restenosis after percutaneous transluminal coronary angioplasty of in-stent restenotic lesions. |
| Q26863362 | Gene delivery technologies for cardiac applications |
| Q46893114 | Gene expression profiling for prediction of response to chemotherapy |
| Q46042292 | Intracoronary beta-irradiation enhances balloon-injury-induced tissue factor expression in the porcine injury model |
| Q44766503 | Is systematic use of drug-eluting stents justified? Arguments in favour |
| Q36691627 | Isolation and expansion of resident cardiac progenitor cells. |
| Q28472148 | Luminal flow amplifies stent-based drug deposition in arterial bifurcations |
| Q35190937 | New approaches to preventing restenosis |
| Q35584009 | One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial |
| Q35591181 | Paclitaxel-eluting stents: are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients |
| Q38084549 | Perioperative management of antiplatelet therapy in patients with drug-eluting stents. |
| Q47341926 | Platelet adhesion to simulated stented surfaces |
| Q49887616 | Predictors of major adverse cardiac events following elective stenting of large coronary arteries. |
| Q57644099 | Propensity score models in observational comparative effectiveness studies: cornerstone of design or statistical afterthought? |
| Q57854573 | Studies on Design Optimization of Coronary Stents |
| Q28551353 | Surface Modification of Biodegradable Polymers towards Better Biocompatibility and Lower Thrombogenicity |
| Q36735675 | The costs and quality-of-life outcomes of drug-eluting coronary stents: a systematic review |
| Q35987013 | The drug-eluting stent information gap. |
| Q45004977 | The national registry EVASTENT: cost-effectiveness analysis of the sirolimus active stent in diabetic and non-diabetic patients |
| Q28287871 | Unconstrained recovery characterization of shape-memory polymer networks for cardiovascular applications |
| Q30958774 | When are drug-eluting stents effective? A critical analysis of the presently available data |
| Q45152233 | Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies? |
Search more.